Gene therapy breakthrough trial targets hepatitis b virus
NCT ID NCT06680232
Summary
This first-in-human study is testing a new gene therapy called PBGENE-HBV for people with chronic hepatitis B. The trial will enroll 45 adults who are already taking medication to control their hepatitis B virus. Researchers will test different doses to check safety and see if the therapy reduces virus levels in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICS ARENSIA Exploratory Medicine SRL
RECRUITINGChisinau, 2025, Moldova
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital/Harvard University
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New Zealand Clinical Research
RECRUITINGAuckland, 1010, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Queen Mary Hospital, The University of Hong Kong
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.